Oligodendrocytes, the Forgotten Target of Gene Therapy DOI Creative Commons
Yasemin Güneş, Catherine Le Stunff, Pierre Bougnères

и другие.

Cells, Год журнала: 2024, Номер 13(23), С. 1973 - 1973

Опубликована: Ноя. 28, 2024

If the billions of oligodendrocytes (OLs) populating central nervous system (CNS) patients could express their feelings, they would undoubtedly tell gene therapists about frustration with other neural cell populations, neurons, microglia, or astrocytes, which have been favorite targets transfer experiments. This review questions why OLs left out most therapy attempts. The first explanation is that pathogenic role still discussed in CNS diseases. Another reason so-called ubiquitous CAG, CBA, CBh, CMV promoters—widely used studies—are unable poorly able to activate transcription episomal transgene copies brought by adeno-associated virus (AAV) vectors OLs. Accordingly, expression has either not found evaluated studies rodents non-human primates. aims current are give rightful place among cells future target and encourage researchers test effect OL transduction various

Язык: Английский

Recognizing Alzheimer's disease from perspective of oligodendrocytes: Phenomena or pathogenesis? DOI Creative Commons
Jingji Wang, Yilan Zhen,

Jun Yang

и другие.

CNS Neuroscience & Therapeutics, Год журнала: 2024, Номер 30(3)

Опубликована: Март 1, 2024

Abstract Background Accumulation of amyloid beta, tau hyperphosphorylation, and microglia activation are the three highly acknowledged pathological factors Alzheimer's disease (AD). However, oligodendrocytes (OLs) were also widely investigated in pathogenesis treatment for AD. Aims We aimed to update regulatory targets differentiation maturation OLs, emphasized key role OLs occurrence Methods This review first concluded OL with AD pathogenesis, then advanced based on both clinic basic experiments. Later, we extensively discussed possible application current progress diagnosis this complex disease. Results Molecules involving OLs’ or maturation, including various transcriptional factors, cholesterol homeostasis regulators, microRNAs could participate Clinical data point towards impairment patients. Basic research further supports central regulation pathologies. Additionally, classic drugs, donepezil, edaravone, fluoxetine, clemastine demonstrate their potential remedying models, new therapeutics from perspective is constantly being developed. Conclusions believe that dysfunction one important Factors regulating might be biomarkers early agents stimulating warrant development anti‐AD drugs.

Язык: Английский

Процитировано

9

Electroacupuncture promotes oligodendrocyte differentiation and myelin repair in a rat model of vascular dementia: Investigation of the mechanism from NF-κB-mediated inflammation DOI
Chang Liu, Huayi Yin, Xiaoyu Chen

и другие.

Neuroscience, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0

Comparative mapping of single‐cell transcriptomic landscapes in neurodegenerative diseases DOI Creative Commons
E. Keats Shwab, Zhaohui Man, Daniel Gingerich

и другие.

Alzheimer s & Dementia, Год журнала: 2025, Номер 21(5)

Опубликована: Май 1, 2025

Abstract INTRODUCTION Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and Parkinson's (PD) represent a spectrum of neurodegenerative diseases (NDDs). Here, we performed the first direct comparison their transcriptomic landscapes. METHODS We profiled whole transcriptomes NDD cortical tissue by single‐nucleus RNA sequencing, using computational analyses to identify common distinct differentially expressed genes (DEGs), pathways, vulnerable disease‐driver cell subtypes, altered cell‐to‐cell interactions. RESULTS The same inhibitory neuron subtype was depleted in both AD DLB. Potentially disease‐driving neuronal subtypes were identified PD Cell–cell communication predicted be increased but decreased DLB PD. DEGs most commonly shared across NDDs within subtypes. Overall, showed greatest divergence, while exhibited an intermediate signature. DISCUSSION These results may help explain clinicopathological these provide unique insights into molecular mechanisms underlying pathogenesis. Highlights population (AD) (DLB). discovered Differentially types. had showing

Язык: Английский

Процитировано

0

The Role of Oligodendrocytes in Neurodegenerative Diseases: Unwrapping the Layers DOI Open Access
Leona Bokulic Panichi, Stefano Stanca,

Cristina Dolciotti

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(10), С. 4623 - 4623

Опубликована: Май 12, 2025

Neurodegenerative diseases (NDs), including Alzheimer's disease, Parkinson's amyotrophic lateral sclerosis/motor neuron and multiple sclerosis, are characterized by progressive loss of neuronal structure function, leading to severe cognitive, motor, behavioral impairments. They pose a significant growing challenge due their rising prevalence impact on global health systems. The societal emotional toll patients, caregivers, healthcare infrastructures is considerable. While progress has been made in elucidating the pathological hallmarks these disorders, underlying cellular molecular mechanisms remain incompletely understood. Increasing evidence implicates oligodendrocytes progenitors-oligodendrocyte progenitor cells (OPCs)-in pathogenesis several NDs, beyond traditionally recognized role demyelinating conditions such as MS. Oligodendrocytes essential for axonal myelination, metabolic support, neural circuit modulation central nervous system. Disruptions oligodendrocyte function myelin integrity-manifesting demyelination, hypomyelination, or dysmyelination-have associated with disease progression various neurodegenerative contexts. This review consolidates recent findings OPCs explores concept plasticity, discusses therapeutic strategies targeting dysfunction. By highlighting emerging research biology, this aims provide short overview its relevance potential advances.

Язык: Английский

Процитировано

0

Molecular profiling of a rat model of vascular dementia: Evidences from proteomics, metabolomics and experimental validations DOI

Jingji Wang,

Xueqing Wang,

Jun Yang

и другие.

Brain Research, Год журнала: 2024, Номер 1846, С. 149254 - 149254

Опубликована: Сен. 26, 2024

Язык: Английский

Процитировано

2

Comparative mapping of single-cell transcriptomic landscapes in neurodegenerative diseases DOI Creative Commons
E. Keats Shwab, Zhaohui Man,

Daniel Oliveros Gingerich

и другие.

Опубликована: Дек. 18, 2024

ABSTRACT INTRODUCTION Alzheimer’s disease (AD), Dementia with Lewy bodies (DLB), and Parkinson’s (PD) represent a spectrum of neurodegenerative disorders (NDDs). Here, we performed the first direct comparison their transcriptomic landscapes. METHODS We profiled whole transcriptomes NDD cortical tissue by snRNA-seq. used computational analyses to identify common distinct differentially expressed genes (DEGs), biological pathways, vulnerable disease-driver cell subtypes, alteration in cell-to-cell interactions. RESULTS The same inhibitory neuron subtype was depleted both AD DLB. Potentially disease-driving neuronal subtypes were present PD Cell-cell communication predicted be increased but decreased DLB PD. DEGs most commonly shared across NDDs within subtypes. Overall, observed greatest divergence between PD, while exhibited an intermediate signature. DISCUSSION These results help explain clinicopathological this group provide unique insights into molecular mechanisms underlying pathogenesis NDDs.

Язык: Английский

Процитировано

2

Role of non-neuronal cells in neurorepair: a focus on proteinopathy and neurodegeneration DOI
Santiago Rodríguez-Carreiro,

Maria del Carmen Nogales,

David Jiménez-Galán

и другие.

Regenerative medicine reports ., Год журнала: 2024, Номер 1(1), С. 31 - 51

Опубликована: Сен. 1, 2024

Despite advances in biomedicine, therapies that prevent neuronal loss have not been effective. Several strategies targeting the defining markers of main neurodegenerative diseases, such as amyloid beta or tau, which are pivotal Alzheimer’s disease frontotemporal dementia, α-synuclein, leading actor Parkinson’s disease, shown limited success. Nevertheless, these proteins do act only neurons but also part a network involving non-neuronal brain cells, astrocytes, microglia and oligodendrocytes, well peripheral immune system. In this review, we aim to cover role central cells proteinopathies associated with amyloid-β objective identifying new options for regenerative medicine aimed at neuroprotection neurorepair.

Язык: Английский

Процитировано

1

Efficient discovery of antibody binding pairs using a photobleaching strategy for bead encoding DOI
Shira Roth,

Tom Ferrante,

David R. Walt

и другие.

Lab on a Chip, Год журнала: 2024, Номер 24(17), С. 4060 - 4072

Опубликована: Янв. 1, 2024

Dye-encoded bead-based assays are widely used for diagnostics. Multiple bead populations required multiplexing and can be produced using different dye colors, labeling levels, or combinations of ratios. Ready-to-use multiplex restrict users to specific targets, costly, require specialized instrumentation. In-house methods produce few plexes many fine-tuning steps. To expand encoding strategies, we present a simple, safe, cost-effective bench-top system generating photobleaching. By photobleaching commercially available dye-encoded magnetic beads durations, three times as differentiable on flow cytometry from single color. Our uses high-power LED module connected light concentrator heat sink. The photobleached in solution homogeneously by constant mixing. We demonstrate this method utilized cross-testing antibodies, which is the first step developing immunoassays. assay multiple encoded conjugated with capture antibodies test binding pairs simultaneously. further number that tested at once, several were same bead, forming pooled assay. predicts performance antibody ultrasensitive Simoa assays, narrowing cross-tested need least two-thirds and, therefore, providing rapid alternative an initial pair screening. other applications, such multiplexing, particles solution.

Язык: Английский

Процитировано

0

Oligodendrocytes, the Forgotten Target of Gene Therapy DOI Creative Commons
Yasemin Güneş, Catherine Le Stunff, Pierre Bougnères

и другие.

Cells, Год журнала: 2024, Номер 13(23), С. 1973 - 1973

Опубликована: Ноя. 28, 2024

If the billions of oligodendrocytes (OLs) populating central nervous system (CNS) patients could express their feelings, they would undoubtedly tell gene therapists about frustration with other neural cell populations, neurons, microglia, or astrocytes, which have been favorite targets transfer experiments. This review questions why OLs left out most therapy attempts. The first explanation is that pathogenic role still discussed in CNS diseases. Another reason so-called ubiquitous CAG, CBA, CBh, CMV promoters—widely used studies—are unable poorly able to activate transcription episomal transgene copies brought by adeno-associated virus (AAV) vectors OLs. Accordingly, expression has either not found evaluated studies rodents non-human primates. aims current are give rightful place among cells future target and encourage researchers test effect OL transduction various

Язык: Английский

Процитировано

0